28 Liberty Street
39th Floor
New York, NY 10005
United States
646 305 6387
https://beyondspringpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 73
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Lan Huang Ph.D. | Co-Founder, Chairman & CEO | N/D | N/D | 1971 |
Mr. Linqing Jia | Co-Founder | N/D | N/D | N/D |
Dr. June Lu Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
Stephen Kilmer | Head of Investor Relations | N/D | N/D | N/D |
Mr. Gregg Russo | Senior Vice President of Human Resources | N/D | N/D | N/D |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
La calificación ISS Governance QuickScore de BeyondSpring Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.